Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00183430 · ClinicalTrials.gov registry record · NA

Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

A NA study, sponsored by Seattle Institute for Biomedical and Clinical Research.

Terminated
Registry status
NA
Development phase
20
Enrollment target

NCT00183430: Clinical Trial NA study, sponsored by Seattle Institute for Biomedical and Clinical Research.

NCT00183430 is a NA study that was terminated before completion, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00183430, a NA study, was terminated before completion, sponsored by Seattle Institute for Biomedical and Clinical Research.

TERMINATED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals taking selective serotonin reuptake inhibitors.

Primary Outcome

The Clinical Global Impression of Change is a 7-point scale that rates global change compared to baseline (1=markedly improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=moderately worse, 7=markedly worse). The Clinical Global Impression of Change is used to determine the impact of treatment effects on meaningful and distinct change in overall sense of well-being and functioning. This outcome measure evaluates change from Baseline to Week 8.

Interventions

  • DRUG Placebo
  • BEHAVIORAL Psychotherapy
  • DRUG Prazosin

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2003-10
Est. Completion 2010-12
Phase NA

Why NCT00183430 stopped before completion

NCT00183430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00183430 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00183430 about?

NCT00183430 is a clinical study titled "Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder". This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals taking selective serotonin reuptake inhibitors.

What is the current status of trial NCT00183430?

This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2003-10. Estimated completion is 2010-12.

What interventions are being tested in trial NCT00183430?

The interventions under investigation include: Placebo (DRUG), Psychotherapy (BEHAVIORAL), Prazosin (DRUG).

Who is sponsoring clinical trial NCT00183430?

This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00183430's enrollment target sits among peer trials

20 1768th of 2000 higher than 140 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00183430, the US trial registry maintained by the National Library of Medicine. NCT00183430 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.